



DEFENSE HEALTH AGENCY
7700 ARLINGTON BOULEVARD, SUITE 5101
FALLS CHURCH, VIRGINIA 22042-5101

February 9, 2018

Licensing Assistance Team
Division of Nuclear Materials Safety
U.S. Nuclear Regulatory Commission, Region 1
2100 Renaissance Blvd., Suite 100
King of Prussia, PA 19406-2713

Re: Defense Health Agency, Nuclear Regulatory Commission License 45-35423-01

Ladies and Gentlemen:

The Defense Health Agency (DHA) appreciates the recent issuing of the Nuclear Regulatory Commission (NRC) License 45-35423-01. Based upon our review, DHA requests two line items are added to ensure patient treatment continues.

DHA originally requested I-131 for diagnosis and treatment as a separate line item. Some therapy procedures are above 200 mCi and won't be covered by lines 6-9 A.

Request add the following new line:

- 6. I-131;
- 7. Any;
- 8. As needed not to exceed 2 Ci (74 gigabecquerels), per site;
- 9. For use in medical diagnosis and therapy for which a written directive is required.

DHA didn't originally request a separate line item for Ra-223 since this was covered under requested statement, 'any byproduct material permitted under 35.300'. Since the 35.500 clause isn't used for Broad Scopes and Ra-223 isn't under Atomic number 83, need a separate line item.

Request add the following new line:


- 6. Ra-223;
- 7. Injectable Liquid (Bayer Healthcare);
- 8. 5 mCi (185 megabecquerels), per site;
- 9. For use in medical as permitted by 35.300 and for research under 10 CFR 35.6.

Please expedite these changes so DHA can continue to provide medical care to our patients.

Re: Defense Health Agency, Nuclear Regulatory Commission License 45-35423-01

If you have any questions regarding this matter, please contact me at harry.m.stewart4.mil@mail.mil or (703) 681-6866.

Sincerely,



H. M. STEWART, JR
LTC, MS, US ARMY
DHA Radiation Safety Director

Copy to: DHA Radiation Safety Committee